1. Modeling the cancer patient with genetically engineered mice
Reade B Roberts, Carlos L Arteaga, David W Threadgill 
Cancer Cell 
Volume 5, Issue 2, Pages (February 2004)
DOI: /S (04)

2. Figure 1
Developmental skin defects in Egfr-deficient mice (A and C) and skin toxicity in patients treated with EGFR inhibitors (B and D)
Gross images of severe skin and hair pathology in a Egfr mutant mouse (A) and folliculitis in a patient susceptible to EGFR inhibition therapy induced skin toxicity (B). Comparative histology of hair follicle in Egfr nullizygous skin (C) and follicle from patient with EGFR therapy-induced folliculitis (D). Rupture of follicular epithelium and strong mixed inflammatory response are evident in both C and D. (B) reprinted with permission from the American Society of Clinical Oncology (Baselga et al., 2002); (C) provided by Laura Hansen (Creighton University); and (D) reprinted with permission from Blackwell Publishing (Busam et al., 2001).
Cancer Cell 2004 5, DOI: ( /S (04) )